查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1941526

中枢神经系统治疗市场规模、份额和趋势分析报告：按疾病、药物类别、分销管道、地区和细分市场预测（2026-2033 年）

Central Nervous System Therapeutics Market Size, Share & Trends Analysis Report By Disease (Neurovascular Diseases, CNS Trauma), By Drug Class, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

中枢神经系统治疗市场概述

2025年全球中枢神经系统治疗市场规模估计为1,385.9亿美元，预计2033年将达到2,733.2亿美元。

预计从 2026 年到 2033 年，中枢神经系统 (CNS) 治疗市场将以 9.1% 的年复合成长率（CAGR）成长。该市场正经历强劲成长，主要原因是神经系统和精神疾病的盛行率不断上升。

世界人口老化，加上现代生活方式的影响，正导致阿兹海默症、帕金森氏症、癫痫、多发性硬化症和精神疾病等疾病的发病率稳定上升。日益加重的疾病负担促使人们对新型和改良治疗方法的需求显着增长。随着对有效治疗方法的需求不断增加，製药和生技公司加大了对中枢神经系统药物研发的投资，各国政府也加大对相关研究倡议的支持力道。

全球人口老化是推动中枢神经系统疾病治疗市场日益增长的最重要因素之一。根据世界卫生组织预测，60岁及以上人口的比例预计将从2015年的约12%翻一番，到2050年达到22%。包括阿兹海默症、帕金森氏症和其他失智症在内的神经退化性疾病主要与老龄化相关，其盛行率随着预期寿命的延长而增加。目前全球有超过5,500万人患有阿兹海默症，预计到2050年，这一数字将成长近三倍。同样，帕金森氏症目前影响着全球约1,000万人，随着人口老化，预计这一数字还将进一步增加。这导致人们对根治性治疗方法的需求日益增长，尤其是那些能够延缓疾病进展或改善这些进行性疾病病理的疗法。儘管神经退化性疾病的发生率不断上升，但目前的治疗选择有限，而且尚无治疗方法。这种情况促使人们增加对新型治疗方法的投资，例如疾病修饰疗法和能够克服血脑障壁的标靶药物递送系统。

老龄化以及现代生活方式因素，例如压力、不良饮食、缺乏运动和环境污染，正在导致神经系统疾病和精神疾病的增加。这些因素与中风、偏头痛、思觉失调症、忧郁症、精神分裂症和躁郁症等精神健康问题的增加密切相关。精神健康问题正成为全球致残的主要原因之一。世界卫生组织估计，全球有超过3亿人患有忧郁症，而且这一数字还在持续成长。精神疾病的这种上升趋势促使人们迫切需要针对忧郁症和思觉失调症等疾病的根本原因开发新的治疗方法。人们对更有效、治疗方法更少且具有长期疗效的治疗方法的需求比以往任何时候都更加迫切。

阿兹海默症率的上升预计将推动市场成长。阿兹海默症是一种全球性流行病，全球整体诊断率约为25%。已开发国家的阿兹海默症阿兹海默症诊断率较高。在北美和一些欧洲国家，诊断率接近50%，而在印度和中国等开发中国家，诊断率约10%至15%。此外，根据美国国家生物技术资讯中心（NCBI）的数据，截至2021年，美国约有620万65岁及以上的老年人患有阿兹海默症，预计到2060年，这一数字将增至约1,380万人。

此外，全球范围内与阿兹海默症相关的失智症发病率和经济负担的不断增加预计将推动市场成长。根据阿兹海默症协会统计，英国约有90万人患有失智症，预计到2040年这一数字将上升至160万人。同年，新增失智症病例预计也将达到20.96万例。

阿兹海默症正逐渐成为神经退化性疾病中最常见的死亡原因，也是导致残疾的主要原因之一。此病在女性的发生率高于男性；每三名患者中就有两名是女性。在全球范围内，阿兹海默症的年龄分布如下：4%的患者年龄在65岁以下，13%的患者年龄在65至74岁之间，44%的患者年龄在75至84岁之间，38%的患者年龄在85岁以上。

目录

第一章调查方法和范围

第二章执行摘要

3. 中枢神经系统治疗市场变数、趋势和范围

  • 市场谱系展望
  • 市场动态
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章 中枢神经系统治疗市场：按疾病分類的商业分析

  • 按疾病分類的市场份额（2025 年和 2033 年）
  • 按疾病分類的市场规模、预测和趋势分析（2021-2033 年）
  • 神经血管疾病
  • 中枢神经系统创伤
  • 心理健康
  • 神经退化性疾病
  • 感染疾病
  • 中枢神经系统癌症
  • 其他的

5. 中枢神经系统药物市场：按药物类别分類的商业分析

  • 按药物类别分類的市场份额（2025 年和 2033 年）
  • 市场规模、预测和趋势分析（按药物类别划分，2021-2033 年）
  • 抗忧郁症
  • 抗精神病药物
  • 抗癫痫药物（AEDs）
  • 多巴胺促效剂
  • 神经保护剂
  • 免疫调节剂
  • 其他的

6. 中枢神经系统治疗市场：按分销管道分類的业务分析

  • 按分销管道分類的市场份额（2025 年和 2033 年）
  • 按分销管道分類的市场规模、预测和趋势分析（2021-2033 年）
  • 医院药房
  • 零售药房
  • 其他的

第七章 中枢神经系统药物市场：区域估算与趋势分析

  • 区域市场占有率分析（2025 年和 2033 年）
  • 区域市场概览
  • 市场规模及预测趋势分析（2021-2033）：
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争情势

  • 参与公司概况
  • 企业市场分析
  • 公司分类
  • 策略规划
  • 公司简介/列表
    • Biogen
    • Otsuka Pharmaceutical Co., Ltd.
    • Eli Lilly and Company
    • Merck &Co., Inc.
    • AstraZeneca
    • Takeda Pharmaceutical Company Limited.
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Johnson &Johnson Services, Inc.
    • Pfizer, Inc.
Product Code: GVR-1-68038-516-8

Central Nervous System Therapeutics Market Summary

The global central nervous system therapeutics market size was estimated at USD 138.59 billion in 2025 and is projected to reach USD 273.32 billion by 2033, growing at a CAGR of 9.1% from 2026 to 2033. The central nervous system (CNS) therapeutics market is experiencing robust growth, driven largely by the rising prevalence of neurological and psychiatric disorders.

As the global population ages, coupled with the impact of modern lifestyle choices, the incidence of diseases such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, and mental health disorders is steadily increasing. This expanding disease burden is catalyzing significant demand for new and improved therapeutic options. As the need for effective treatments grows, pharmaceutical and biotechnology companies are ramping up investments in CNS drug development, and governments are offering increased support for research initiatives.

The global aging population is one of the most significant drivers of rising disease prevalence in the CNS therapeutics market. According to the WHO, the ratio of the world's population aged 60 years and older is anticipated to double by 2050, from approximately 12% in 2015 to 22%. Neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and other dementias, are primarily age-related and are becoming more prevalent as life expectancy increases. Alzheimer's disease, which currently affects more than 55 million people worldwide, is predicted to nearly triple by 2050. Similarly, Parkinson's disease affects an estimated 10 million people globally, and this number is expected to rise due to the aging population. As a result, there is a growing demand for effective treatments, particularly those that can delay the progression of these debilitating diseases or modify their course. Despite the increasing prevalence, current treatment options for neurodegenerative diseases remain limited, with no cure available. This has led to increased investment in novel therapies, including disease-modifying treatments and targeted drug delivery systems aimed at overcoming the blood-brain barrier.

Beyond aging, modern lifestyle factors such as stress, poor diet, sedentary behavior, and environmental pollution are contributing to the rising prevalence of both neurological and psychiatric disorders. These factors have been linked to an increase in stroke, migraine, and mental health conditions such as anxiety, depression, schizophrenia, and bipolar disorder. Mental health issues are becoming a leading cause of disability worldwide. The WHO estimates that over 300 million people suffer from depression globally, and the number is steadily increasing. This growing prevalence of psychiatric disorders is pushing for new therapeutic options that address the root causes of conditions such as depression and schizophrenia. The need for treatments that are more effective, have fewer side effects, and offer better long-term outcomes has never been greater.

The rising prevalence of Alzheimer's disease is expected to boost market growth. Alzheimer's disease is a global epidemic, and its diagnosis rate is about 25% globally. The diagnosis rate of Alzheimer's disease is high in developed countries. In North America and some European countries, the diagnosis rate of Alzheimer's disease is nearly 50%, whereas, in developing countries such as India & China, it varies from 10%-15% of total Alzheimer's cases. In addition, according to NCBI, in 2021, about 6.2 million people aged 65 and above living in America were suffering from Alzheimer's disease, which is estimated to increase to around 13.8 million by 2060.

Furthermore, an increase in the incidence and cost burden of dementia associated with Alzheimer's disease worldwide is expected to boost market growth. According to the Alzheimer's Society, there are around 900,000 people living with dementia in the UK, and it is projected to rise to 1.6 million by 2040 and the incidence of dementia will be 209,600 in the same year.

Alzheimer's disease is becoming the most common cause of death in neurodegenerative diseases and a common cause of physical disability. The disease is most common in females as compared to males. For instance, two in three people with the disease are women. The age distribution for Alzheimer's disease across the globe includes 4% aged 65 or younger, 13% aged between 65 and 74, 44% aged 75 to 84, and 38% aged 85 or older.

Global Central Nervous System Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global central nervous system therapeutics market report based on disease, drug class, distribution channel, and region:

  • Disease Outlook (Revenue, USD Million, 2021 - 2033)
  • Neurovascular Diseases
  • CNS Trauma
  • Mental Health
    • Anxiety Disorders
    • Epilepsy
    • Mood Disorders
    • Psychotic Disorders
    • Others
  • Neurodegenerative Diseases
    • Alzheimer's Disease
    • Parkinsosn's Disease
    • Multiple Sclerosis
    • Huntington's Disease
    • Amytrophic Lateral Sclerosis
    • Others
  • Infectious Diseases
  • CNS Cancer
  • Others
  • Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
  • Antidepressants
  • Antipsychotics
  • Antiepileptics (AEDs)
  • Dopaminergic Agents
  • Neuroprotective Agents
  • Immunomodulators
  • Others
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacy
  • Retail Pharmacy
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease
    • 1.2.2. Drug Class
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Central Nervous System Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Central Nervous System Therapeutics Market: Disease Business Analysis

  • 4.1. Disease Market Share, 2025 & 2033
  • 4.2. Disease Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Disease, 2021 to 2033 (USD Million)
  • 4.4. Neurovascular Diseases
    • 4.4.1. Neurovascular Diseases Market, 2021 - 2033 (USD Million)
  • 4.5. CNS Trauma
    • 4.5.1. CNS Trauma Market, 2021 - 2033 (USD Million)
  • 4.6. Mental Health
    • 4.6.1. Mental Health Market, 2021 - 2033 (USD Million)
    • 4.6.2. Anxiety Disorders
      • 4.6.2.1. Anxiety Disorders Market, 2021 - 2033 (USD Million)
    • 4.6.3. Epilepsy
      • 4.6.3.1. Epilepsy Market, 2021 - 2033 (USD Million)
    • 4.6.4. Mood Disorders
      • 4.6.4.1. Mood Disorders Market, 2021 - 2033 (USD Million)
    • 4.6.5. Psychotic Disorders
      • 4.6.5.1. Psychotic Disorders Market, 2021 - 2033 (USD Million)
    • 4.6.6. Others
      • 4.6.6.1. Others Market, 2021 - 2033 (USD Million)
  • 4.7. Neurodegenerative Diseases
    • 4.7.1. Neurodegenerative Diseases Market, 2021 - 2033 (USD Million)
    • 4.7.2. Alzheimer's Disease
      • 4.7.2.1. Alzheimer's Disease Market, 2021 - 2033 (USD Million)
    • 4.7.3. Parkinsosn's Disease
      • 4.7.3.1. Parkinsosn's Disease Market, 2021 - 2033 (USD Million)
    • 4.7.4. Multiple Sclerosis
      • 4.7.4.1. Multiple Sclerosis Market, 2021 - 2033 (USD Million)
    • 4.7.5. Huntington's Disease
      • 4.7.5.1. Huntington's Disease Market, 2021 - 2033 (USD Million)
    • 4.7.6. Amytrophic Lateral Sclerosis
      • 4.7.6.1. Amytrophic Lateral Sclerosis Market, 2021 - 2033 (USD Million)
    • 4.7.7. Others
      • 4.7.7.1. Others Market, 2021 - 2033 (USD Million)
  • 4.8. Infectious Diseases
    • 4.8.1. Infectious Diseases Market, 2021 - 2033 (USD Million)
  • 4.9. CNS Cancer
    • 4.9.1. CNS Cancer Market, 2021 - 2033 (USD Million)
  • 4.10. Others
    • 4.10.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Central Nervous System Therapeutics Market: Drug Class Business Analysis

  • 5.1. Drug Class Market Share, 2025 & 2033
  • 5.2. Drug Class Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Drug class, 2021 to 2033 (USD Million)
  • 5.4. Antidepressants
    • 5.4.1. Antidepressants Market, 2021 - 2033 (USD Million)
  • 5.5. Antipsychotics
    • 5.5.1. Antipsychotics Market, 2021 - 2033 (USD Million)
  • 5.6. Antiepileptics (AEDs)
    • 5.6.1. Antiepileptics (AEDs) Market, 2021 - 2033 (USD Million)
  • 5.7. Dopaminergic Agents
    • 5.7.1. Dopaminergic Agents Market, 2021 - 2033 (USD Million)
  • 5.8. Neuroprotective Agents
    • 5.8.1. Neuroprotective Agents Market, 2021 - 2033 (USD Million)
  • 5.9. Immunomodulators
    • 5.9.1. Immunomodulators Market, 2021 - 2033 (USD Million)
  • 5.10. Others
    • 5.10.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Central Nervous System Therapeutics Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2025 & 2033
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution channel, 2021 to 2033 (USD Million)
  • 6.4. Hospital Pharmacy
    • 6.4.1. Hospital Pharmacy Market, 2021 - 2033 (USD Million)
  • 6.5. Retail Pharmacy
    • 6.5.1. Retail Pharmacy Market, 2021 - 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Central Nervous System Therapeutics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2025 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Central Nervous System Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Drug Class Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Drug Class Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. U.S. Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Drug Class Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Drug Class Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. Uk Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Drug Class Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Drug Class Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Drug Class Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Drug Class Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Drug Class Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Drug Class Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Drug Class Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Drug Class Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Drug Class Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Drug Class Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Drug Class Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Drug Class Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Drug Class Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Drug Class Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Japan Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Drug Class Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. China Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Drug Class Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Drug Class Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Drug Class Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Drug Class Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Central Nervous System Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Biogen
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Disease Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Otsuka Pharmaceutical Co., Ltd.
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Disease Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Eli Lilly and Company
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Disease Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Merck & Co., Inc.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Disease Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. AstraZeneca
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Disease Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Takeda Pharmaceutical Company Limited.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Disease Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Novartis AG
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Disease Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Teva Pharmaceutical Industries Ltd.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Disease Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Johnson & Johnson Services, Inc.
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Disease Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Pfizer, Inc.
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Disease Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global central nervous system therapeutics market, by region, 2021 - 2033 (USD Billion)
  • Table 4 Global central nervous system therapeutics market, by disease, 2021 - 2033 (USD Billion)
  • Table 5 Global central nervous system therapeutics market, by drug class, 2021 - 2033 (USD Billion)
  • Table 6 Global central nervous system therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 7 North America central nervous system therapeutics market, by country, 2021 - 2033 (USD Billion)
  • Table 8 North America central nervous system therapeutics market, by disease, 2021 - 2033 (USD Billion)
  • Table 9 North America central nervous system therapeutics market, by drug class, 2021 - 2033 (USD Billion)
  • Table 10 North America central nervous system therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 11 US central nervous system therapeutics market, by disease, 2021 - 2033 (USD Billion)
  • Table 12 US central nervous system therapeutics market, by drug class, 2021 - 2033 (USD Billion)
  • Table 13 US Central nervous system therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 14 Canada central nervous system therapeutics market, by disease, 2021 - 2033 (USD Billion)
  • Table 15 Canada central nervous system therapeutics market, by drug class, 2021 - 2033 (USD Billion)
  • Table 16 Canada central nervous system therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 17 Mexico central nervous system therapeutics market, by disease, 2021 - 2033 (USD Billion)
  • Table 18 Mexico central nervous system therapeutics market, by drug class, 2021 - 2033 (USD Billion)
  • Table 19 Mexico central nervous system therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 20 Europe central nervous system therapeutics market, by country, 2021 - 2033 (USD Billion)
  • Table 21 Europe central nervous system therapeutics market, by disease, 2021 - 2033 (USD Billion)
  • Table 22 Europe central nervous system therapeutics market, by drug class, 2021 - 2033 (USD Billion)
  • Table 23 Europe central nervous system therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 24 UK central nervous system therapeutics market, by disease, 2021 - 2033 (USD Billion)
  • Table 25 UK central nervous system therapeutics market, by drug class, 2021 - 2033 (USD Billion)
  • Table 26 UK Central nervous system therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 27 Germany central nervous system therapeutics market, by disease, 2021 - 2033 (USD Billion)
  • Table 28 Germany central nervous system therapeutics market, by drug class, 2021 - 2033 (USD Billion)
  • Table 29 Germany central nervous system therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 30 France central nervous system therapeutics market, by disease, 2021 - 2033 (USD Billion)
  • Table 31 France central nervous system therapeutics market, by drug class, 2021 - 2033 (USD Billion)
  • Table 32 France Central nervous system therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 33 Italy central nervous system therapeutics market, by disease, 2021 - 2033 (USD Billion)
  • Table 34 Italy central nervous system therapeutics market, by drug class, 2021 - 2033 (USD Billion)
  • Table 35 Italy central nervous system therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 36 Spain central nervous system therapeutics market, by disease, 2021 - 2033 (USD Billion)
  • Table 37 Spain central nervous system therapeutics market, by drug class, 2021 - 2033 (USD Billion)
  • Table 38 Spain central nervous system therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 39 Norway central nervous system therapeutics market, by disease, 2021 - 2033 (USD Billion)
  • Table 40 Norway central nervous system therapeutics market, by drug class, 2021 - 2033 (USD Billion)
  • Table 41 Norway Central nervous system therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 42 Denmark central nervous system therapeutics market, by disease, 2021 - 2033 (USD Billion)
  • Table 43 Denmark central nervous system therapeutics market, by drug class, 2021 - 2033 (USD Billion)
  • Table 44 Denmark central nervous system therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 45 Sweden central nervous system therapeutics market, by disease, 2021 - 2033 (USD Billion)
  • Table 46 Sweden central nervous system therapeutics market, by drug class, 2021 - 2033 (USD Billion)
  • Table 47 Sweden central nervous system therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 48 Asia Pacific central nervous system therapeutics market, by country, 2021 - 2033 (USD Billion)
  • Table 49 Asia Pacific central nervous system therapeutics market, by disease, 2021 - 2033 (USD Billion)
  • Table 50 Asia Pacific central nervous system therapeutics market, by drug class, 2021 - 2033 (USD Billion)
  • Table 51 Asia Pacific central nervous system therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 52 Japan central nervous system therapeutics market, by disease, 2021 - 2033 (USD Billion)
  • Table 53 Japan central nervous system therapeutics market, by drug class, 2021 - 2033 (USD Billion)
  • Table 54 Japan central nervous system therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 55 China central nervous system therapeutics market, by disease, 2021 - 2033 (USD Billion)
  • Table 56 China central nervous system therapeutics market, by drug class, 2021 - 2033 (USD Billion)
  • Table 57 China central nervous system therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 58 India central nervous system therapeutics market, by disease, 2021 - 2033 (USD Billion)
  • Table 59 India central nervous system therapeutics market, by drug class, 2021 - 2033 (USD Billion)
  • Table 60 India central nervous system therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 61 Australia central nervous system therapeutics market, by disease, 2021 - 2033 (USD Billion)
  • Table 62 Australia central nervous system therapeutics market, by drug class, 2021 - 2033 (USD Billion)
  • Table 63 Australia central nervous system therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 64 South Korea central nervous system therapeutics market, by disease, 2021 - 2033 (USD Billion)
  • Table 65 South Korea central nervous system therapeutics market, by drug class, 2021 - 2033 (USD Billion)
  • Table 66 South Korea central nervous system therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 67 Thailand central nervous system therapeutics market, by disease, 2021 - 2033 (USD Billion)
  • Table 68 Thailand central nervous system therapeutics market, by drug class, 2021 - 2033 (USD Billion)
  • Table 69 Thailand central nervous system therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 70 Latin America central nervous system therapeutics market, by country, 2021 - 2033 (USD Billion)
  • Table 71 Latin America central nervous system therapeutics market, by disease, 2021 - 2033 (USD Billion)
  • Table 72 Latin America central nervous system therapeutics market, by drug class, 2021 - 2033 (USD Billion)
  • Table 73 Latin America central nervous system therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 74 Brazil central nervous system therapeutics market, by disease, 2021 - 2033 (USD Billion)
  • Table 75 Brazil central nervous system therapeutics market, by drug class, 2021 - 2033 (USD Billion)
  • Table 76 Brazil central nervous system therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 77 Argentina central nervous system therapeutics market, by disease, 2021 - 2033 (USD Billion)
  • Table 78 Argentina central nervous system therapeutics market, by drug class, 2021 - 2033 (USD Billion)
  • Table 79 Argentina central nervous system therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 80 Middle East & Africa Central nervous system therapeutics market, by country, 2021 - 2033 (USD Billion)
  • Table 81 Middle East & Africa central nervous system therapeutics market, by disease, 2021 - 2033 (USD Billion)
  • Table 82 Middle East & Africa central nervous system therapeutics market, by drug class, 2021 - 2033 (USD Billion)
  • Table 83 Middle East & Africa central nervous system therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 84 South Africa central nervous system therapeutics market, by disease, 2021 - 2033 (USD Billion)
  • Table 85 South Africa central nervous system therapeutics market, by drug class, 2021 - 2033 (USD Billion)
  • Table 86 South Africa central nervous system therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 87 Saudi Arabia central nervous system therapeutics market, by disease, 2021 - 2033 (USD Billion)
  • Table 88 Saudi Arabia central nervous system therapeutics market, by drug class, 2021 - 2033 (USD Billion)
  • Table 89 Saudi Arabia central nervous system therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 90 UAE central nervous system therapeutics market, by disease, 2021 - 2033 (USD Billion)
  • Table 91 UAE central nervous system therapeutics market, by drug class, 2021 - 2033 (USD Billion)
  • Table 92 UAE central nervous system therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 93 Kuwait central nervous system therapeutics market, by disease, 2021 - 2033 (USD Billion)
  • Table 94 Kuwait central nervous system therapeutics market, by drug class, 2021 - 2033 (USD Billion)
  • Table 95 Kuwait central nervous system therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 Central nervous system therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Disease and drug class (USD Billion)
  • Fig. 10 Distribution channel outlook
  • Fig. 11 Competitive landscape
  • Fig. 12 Central nervous system therapeutics market dynamics
  • Fig. 13 Central nervous system therapeutics market: Porter's five forces analysis
  • Fig. 14 Central nervous system therapeutics market: PESTLE analysis
  • Fig. 15 Central nervous system therapeutics market Disease segment dashboard
  • Fig. 16 Central nervous system therapeutics market: Disease market share analysis, 2025 & 2033
  • Fig. 17 Neurovascular diseases market, 2021 - 2033 (USD Billion)
  • Fig. 18 CNS trauma market, 2021 - 2033 (USD Billion)
  • Fig. 19 Mental health market, 2021 - 2033 (USD Billion)
  • Fig. 20 Anxiety disorders market, 2021 - 2033 (USD Billion)
  • Fig. 21 Epilepsy market, 2021 - 2033 (USD Billion)
  • Fig. 22 Mood disorders market, 2021 - 2033 (USD Billion)
  • Fig. 23 Psychotic disorders market, 2021 - 2033 (USD Billion)
  • Fig. 24 Others market, 2021 - 2033 (USD Billion)
  • Fig. 25 Neurodegenerative diseases market, 2021 - 2033 (USD Billion)
  • Fig. 26 Alzheimer's disease market, 2021 - 2033 (USD Billion)
  • Fig. 27 Parkinsosn's disease market, 2021 - 2033 (USD Billion)
  • Fig. 28 Multiple sclerosis market, 2021 - 2033 (USD Billion)
  • Fig. 29 Huntington's disease market, 2021 - 2033 (USD Billion)
  • Fig. 30 Amytrophic lateral sclerosis market, 2021 - 2033 (USD Billion)
  • Fig. 31 Others market, 2021 - 2033 (USD Billion)
  • Fig. 32 Infectious diseases market, 2021 - 2033 (USD Billion)
  • Fig. 33 CNS cancer market, 2021 - 2033 (USD Billion)
  • Fig. 34 Others market, 2021 - 2033 (USD Billion)
  • Fig. 35 Central nervous system therapeutics market: Drug class segment dashboard
  • Fig. 36 Central nervous system therapeutics market: Drug class market share analysis, 2025 & 2033
  • Fig. 37 Anesthetics market, 2021 - 2033 (USD Billion)
  • Fig. 38 Anticonvulsants market, 2021 - 2033 (USD Billion)
  • Fig. 39 Antiemetics market, 2021 - 2033 (USD Billion)
  • Fig. 40 CNS stimulants market, 2021 - 2033 (USD Billion)
  • Fig. 41 Pain relievers market, 2021 - 2033 (USD Billion)
  • Fig. 42 Others market, 2021 - 2033 (USD Billion)
  • Fig. 43 Central nervous system therapeutics market: Distribution channel segment dashboard
  • Fig. 44 Central nervous system therapeutics market: Distribution channel market share analysis, 2025 & 2033
  • Fig. 45 Hospital pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 46 Retail pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 47 Others market, 2021 - 2033 (USD Billion)
  • Fig. 48 Central nervous system therapeutics market revenue, by region
  • Fig. 49 Regional marketplace: Key takeaways
  • Fig. 50 Regional marketplace: Key takeaways
  • Fig. 51 North America central nervous system therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 52 U.S. country dynamics
  • Fig. 53 U.S. central nervous system therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 54 Canada country dynamics
  • Fig. 55 Canada central nervous system therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 56 Mexico country dynamics
  • Fig. 57 Mexico central nervous system therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 58 Europe central nervous system therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 59 UK country dynamics
  • Fig. 60 UK central nervous system therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 61 Germany country dynamics
  • Fig. 62 Germany central nervous system therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 63 France country dynamics
  • Fig. 64 France central nervous system therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 65 Italy country dynamics
  • Fig. 66 Italy central nervous system therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 67 Spain country dynamics
  • Fig. 68 Spain central nervous system therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 69 Norway country dynamics
  • Fig. 70 Norway central nervous system therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 71 Sweden country dynamics
  • Fig. 72 Sweden central nervous system therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 73 Denmark country dynamics
  • Fig. 74 Denmark central nervous system therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 75 Asia Pacific central nervous system therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 76 Japan country dynamics
  • Fig. 77 Japan central nervous system therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 78 China country dynamics
  • Fig. 79 China central nervous system therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 80 India country dynamics
  • Fig. 81 India central nervous system therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 82 Australia country dynamics
  • Fig. 83 Australia central nervous system therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 84 South Korea country dynamics
  • Fig. 85 South Korea central nervous system therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 86 Thailand country dynamics
  • Fig. 87 Thailand central nervous system therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 88 Latin America central nervous system therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 89 Brazil country dynamics
  • Fig. 90 Brazil central nervous system therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 91 Argentina country dynamics
  • Fig. 92 Argentina central nervous system therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 93 MEA central nervous system therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 94 South Africa country dynamics
  • Fig. 95 South Africa central nervous system therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 96 Saudi Arabia country dynamics
  • Fig. 97 Saudi Arabia central nervous system therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 98 UAE country dynamics
  • Fig. 99 UAE central nervous system therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 100 Kuwait country dynamics
  • Fig. 101 Kuwait central nervous system therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 102 Company categorization
  • Fig. 103 Company market position analysis
  • Fig. 104 Strategic framework